Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice
about
Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cellsStrategies to target long-lived plasma cells for treating hemophilia A inhibitors.Adeno-Associated Viral Vectors at the Frontier between Tolerance and Immunity.Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in children affected by Pompe Disease.A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
P2860
Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-CD20 as the B-Cell Target ...... in Hemophilia a Inhibitor Mice
@en
Anti-CD20 as the B-Cell Target ...... n Hemophilia a Inhibitor Mice.
@nl
type
label
Anti-CD20 as the B-Cell Target ...... in Hemophilia a Inhibitor Mice
@en
Anti-CD20 as the B-Cell Target ...... n Hemophilia a Inhibitor Mice.
@nl
prefLabel
Anti-CD20 as the B-Cell Target ...... in Hemophilia a Inhibitor Mice
@en
Anti-CD20 as the B-Cell Target ...... n Hemophilia a Inhibitor Mice.
@nl
P2093
P2860
P921
P356
P1476
Anti-CD20 as the B-Cell Target ...... in Hemophilia a Inhibitor Mice
@en
P2093
Carol H Miao
Chao Lien Liu
Chérie L Butts
Jacqueline Lin
Peiqing Ye
P2860
P356
10.3389/FIMMU.2013.00502
P577
2014-01-06T00:00:00Z